Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference
March 29, 2016
"We had presented preliminary results from our trial at AOGIN in March. These data further validate the efficacy of the Cervista HPV HR test for identifying patients at risk of developing or harboring cervical neoplasia," said Jerome Belinson, M.D., Professor of Surgery, Section of Gynecologic Oncology at the Cleveland Clinic and President of Preventive Oncology International. "Our analysis clearly showed that both of these methods performed well and with similar overall accuracy."
"The conclusions of this study should not be under estimated. This is the first head-to-head clinical study to date comparing clinical performance of Cervista HPV HR and Hybrid-Capture 2," said Edward Evantash, M.D., Medical Director and Vice President of Medical Affairs at Hologic. "These clinical data, in combination with its specific advantages in HPV testing, further demonstrate the additional value Cervista HPV brings to overall patient care."
SOURCE Hologic, Inc.